Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy
China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...
Siemens Lays Foundation for New Medical Equipment Base in Shenzhen
Siemens (Shenzhen) Magnetic Resonance Co., Ltd., a wholly-owned subsidiary of Siemens Ltd., China, has officially...
Fujian Haixi Pharmaceuticals Files for Hong Kong IPO
China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...
SciClone and Menarini Submit NDA for Vaborem in China
China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...
Servier and Google Cloud Extend Partnership to Advance AI in Drug Development
France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...
Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials
Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...
Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...
Boston Scientific’s FARAPULSE and WATCHMAN FLX Studies Show Positive Results
US major Boston Scientific Corporation (NYSE: BSX) has announced the presentation of positive results from...
Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced receiving clinical clearance from the...
Zhejiang Huahai’s HB0056 Approved for US Phase I Asthma Trial
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval from...
Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...
CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...
Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...
ConjuStar Completes $15 Million Pre-A+ Financing Round
ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...
Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey
On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical...
GE Healthcare and Sutter Health Form $1B Care Alliance
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has formed...
HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...
Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer
China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...
Wepon Medical’s WP107 Receives FDA Approval for gMG Clinical Trial
China-based Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced receiving clinical trial approval...
Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...